Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients

Background: Imatinib is known as the drug of choice for treatment of chronic myeloid leukemia (CML). For adults the recommended daily dosage of 400 mg requires simultaneous intake of up to four capsules or tablets each 100 mg. A new 400 mg film coated tablet developed due to the need to swallow mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohajeri, Ehsan, Kalantari-Khandani, Behjat, Pardakhty, Abbas, Safavi, Moeinadin, Ansari, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748686/
https://www.ncbi.nlm.nih.gov/pubmed/26865926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748686/
https://www.ncbi.nlm.nih.gov/pubmed/26865926

Ejemplares similares